Sec Form 4 Filing - Morrison Susan @ TANDEM DIABETES CARE INC - 2020-07-31

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Morrison Susan
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP & Chief Admin. Officer
(Last) (First) (Middle)
C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET
3. Date of Earliest Transaction (MM/DD/YY)
07/31/2020
(Street)
SAN DIEGO, CA92121
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/31/2020 M( 1 ) 30,000 A $ 2.59 36,256 D
Common Stock 07/31/2020 M( 1 ) 20,000 A $ 18.86 56,256 D
Common Stock 07/31/2020 S( 2 ) 1,950 D $ 105.8465 ( 3 ) 54,306 D
Common Stock 07/31/2020 S( 2 ) 2,894 D $ 106.9351 ( 4 ) 51,412 D
Common Stock 07/31/2020 S( 2 ) 18,672 D $ 108.0587 ( 5 ) 32,740 D
Common Stock 07/31/2020 S( 2 ) 15,001 D $ 108.914 ( 6 ) 17,739 D
Common Stock 07/31/2020 S( 2 ) 10,213 D $ 109.7885 ( 7 ) 7,526 D
Common Stock 07/31/2020 S( 2 ) 1,270 D $ 110.589 ( 8 ) 6,256 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option $ 2.59 07/31/2020 M 30,000 ( 9 ) ( 10 ) Common Stock 30,000 $ 0 0 D
Stock Option $ 18.86 07/31/2020 M 20,000 ( 11 ) ( 10 ) Common Stock 20,000 $ 0 80,000 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Morrison Susan
C/O TANDEM DIABETES CARE, INC.
11075 ROSELLE STREET
SAN DIEGO, CA92121
EVP & Chief Admin. Officer
Signatures
s/ Leigh A. Vosseller, Attorney-in-Fact for Susan M. Morrison 08/04/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Represents shares of common stock received upon exercise of a stock option award.
( 2 )The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2018.
( 3 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $105.22 to $106.17. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 4 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $106.36 to $107.35. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 5 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $107.43 to $108.43. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 6 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $108.48 to $109.47. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 7 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $109.50 to $110.36. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 8 )The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $110.50 to $110.67. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
( 9 )Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares vested in twelve (12) equal monthly installments thereafter.
( 10 )The expiration date for these options is 10 years from the date of grant.
( 11 )The option vested as to fifty percent (50%) of the underlying shares on 06/14/2019, and the remaining shares vested in twelve (12) equal monthly installments thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.